The use of combination therapy for the improvement of colistin activity against bacterial biofilm.
Abduladheem Turki JalilRawaa Turki Abdulghafoor AlraweMontaha A Al-SaffarMurtadha Lafta ShaghnabMuna S MerzaMunther AbosaoodaRahim LatefPublished in: Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] (2023)
Colistin is used as a last resort for the management of infections caused by multi-drug resistant (MDR) bacteria. However, the use of this antibiotic could lead to different side effects, such as nephrotoxicity, in most patients, and the high prevalence of colistin-resistant strains restricts the use of colistin in the clinical setting. Additionally, colistin could induce resistance through the increased formation of biofilm; biofilm-embedded cells are highly resistant to antibiotics, and as with other antibiotics, colistin is impaired by bacteria in the biofilm community. In this regard, the researchers used combination therapy for the enhancement of colistin activity against bacterial biofilm, especially MDR bacteria. Different antibacterial agents, such as antimicrobial peptides, bacteriophages, natural compounds, antibiotics from different families, N-acetylcysteine, and quorum-sensing inhibitors, showed promising results when combined with colistin. Additionally, the use of different drug platforms could also boost the efficacy of this antibiotic against biofilm. The mentioned colistin-based combination therapy not only could suppress the formation of biofilm but also could destroy the established biofilm. These kinds of treatments also avoided the emergence of colistin-resistant subpopulations, reduced the required dosage of colistin for inhibition of biofilm, and finally enhanced the dosage of this antibiotic at the site of infection. However, the exact interaction of colistin with other antibacterial agents has not been elucidated yet; therefore, further studies are required to identify the precise mechanism underlying the efficient removal of biofilms by colistin-based combination therapy.
Keyphrases
- pseudomonas aeruginosa
- acinetobacter baumannii
- drug resistant
- multidrug resistant
- escherichia coli
- combination therapy
- biofilm formation
- cystic fibrosis
- klebsiella pneumoniae
- gram negative
- staphylococcus aureus
- candida albicans
- healthcare
- chronic kidney disease
- end stage renal disease
- cell death
- molecular dynamics
- signaling pathway
- anti inflammatory